Literature DB >> 11375337

Assessment of hepatic insulin action in obese type 2 diabetic patients.

P Staehr1, O Hother-Nielsen, K Levin, J J Holst, H Beck-Nielsen.   

Abstract

Defects in hepatic insulin action in type 2 diabetes and its possible underlying mechanisms were assessed in euglycemic-hyperinsulinemic clamp studies, using improved tracer methods (constant specific activity technique). Ten obese diabetic patients (age 54 years, BMI 29 +/- 0.5 kg/m(2)) and ten matched control subjects were studied at baseline (after an overnight fast) and during insulin infusions of 20- and 40-mU. m(-2). min(-1). In the diabetic patients, plasma glucose levels were normalized overnight before the studies by low-dose insulin infusion. Hepatic sinusoidal insulin levels were estimated, and plasma levels of free fatty acids (FFAs) and glucagon were determined to assess the direct and indirect effects of insulin on hepatic glucose production (HGP) in type 2 diabetes. Baseline rates of HGP (86 +/- 3 vs. 76 +/- 3 mg. m(-2). min(-1), P < 0.05) were slightly elevated in the diabetic patients compared with control subjects, despite much higher hepatic sinusoidal insulin levels (26 +/- 3 vs. 12 +/- 2 mU/l, P < 0.001). Consequently, a marked defect in the direct (hepatic) effect of insulin on HGP appeared to be present at low insulin levels. However, in response to a small increase in baseline hepatic sinusoidal insulin levels of 11 mU/l (26 +/- 3 to 37 +/- 3 mU/l, P < 0.05) in the 20-mU clamp, a marked suppression of HGP was observed in the diabetic patients (86 +/- 3 to 32 +/- 5 mg. m(-2). min(-1), P < 0.001), despite only minimal changes in FFAs (0.33 +/- 0.05 to 0.25 +/- 0.05 mmol/l, NS) and glucagon (14 +/- 1 to 11 +/- 2 pmol/l, P < 0.05) levels, suggesting that the impairment in the direct effect of insulin can be overcome by a small increase in insulin levels. Compared with control subjects, suppression of HGP in the diabetic patients was slightly impaired in the 20-mU clamp (32 +/- 5 vs. 22 +/- 4 mg. m(-2). min(-1), P < 0.05) but not in the 40-mU clamp (25 +/- 2 vs. 21 +/- 3 mg. m(-2). min(-1), NS). In the 20-mU clamp, hepatic sinusoidal insulin levels in the diabetic patients were comparable with control subjects (37 +/- 3 vs. 36 +/- 3 mU/l, NS), whereas both FFA and glucagon levels were higher (i.e., less suppressed) and correlated with the rates of HGP (R = 0.71, P < 0.02; and R = 0.69, P < 0.05, respectively). Thus, at this insulin level impaired indirect (extrahepatic) effects of insulin seemed to prevail. In conclusion, hepatic insulin resistance is present in obese type 2 diabetic patients but is of quantitative significance only at low physiological insulin levels. Defects in both the direct and the indirect effects of insulin on HGP appear to contribute to this resistance.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11375337     DOI: 10.2337/diabetes.50.6.1363

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  17 in total

Review 1.  Is hepatic glucose production increased in type 2 diabetes mellitus?

Authors:  Henning Beck-Nielsen; Ole Hother-Nielsen; Peter Staehr
Journal:  Curr Diab Rep       Date:  2002-06       Impact factor: 4.810

Review 2.  The role of the liver in type 2 diabetes.

Authors:  Peter Staehr; Ole Hother-Nielsen; Henning Beck-Nielsen
Journal:  Rev Endocr Metab Disord       Date:  2004-05       Impact factor: 6.514

3.  Non-esterified fatty acid concentrations are independently associated with hepatic steatosis in obese subjects.

Authors:  H B Holt; S H Wild; P J Wood; J Zhang; A A Darekar; K Dewbury; R B Poole; R I G Holt; D I Phillips; C D Byrne
Journal:  Diabetologia       Date:  2005-12-02       Impact factor: 10.122

4.  Simple modeling allows prediction of steady-state glucose disposal rate from early data in hyperinsulinemic glucose clamps.

Authors:  Pooja Singal; Ranganath Muniyappa; Robin Chisholm; Gail Hall; Hui Chen; Michael J Quon; Kieren J Mather
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-11-17       Impact factor: 4.310

5.  [13C]glucose breath testing provides a noninvasive measure of insulin resistance: calibration analyses against clamp studies.

Authors:  Maysa Hussain; Morteza Jangorbhani; Sally Schuette; Robert V Considine; Robin L Chisholm; Kieren J Mather
Journal:  Diabetes Technol Ther       Date:  2013-10-11       Impact factor: 6.118

Review 6.  Oral insulin: the rationale for this approach and current developments.

Authors:  Ehud Arbit; Miriam Kidron
Journal:  J Diabetes Sci Technol       Date:  2009-05-01

7.  Insulin's direct effects on the liver dominate the control of hepatic glucose production.

Authors:  Dale S Edgerton; Margaret Lautz; Melanie Scott; Carrie A Everett; Kathryn M Stettler; Doss W Neal; Chang A Chu; Alan D Cherrington
Journal:  J Clin Invest       Date:  2006-02       Impact factor: 14.808

8.  Hepatic steatosis does not cause insulin resistance in people with familial hypobetalipoproteinaemia.

Authors:  M E Visser; N M Lammers; A J Nederveen; M van der Graaf; A Heerschap; M T Ackermans; H P Sauerwein; E S Stroes; M J Serlie
Journal:  Diabetologia       Date:  2011-05-06       Impact factor: 10.122

Review 9.  Effects of bariatric surgery on glucose homeostasis and type 2 diabetes.

Authors:  David Bradley; Faidon Magkos; Samuel Klein
Journal:  Gastroenterology       Date:  2012-08-08       Impact factor: 22.682

10.  Pharmacokinetic and pharmacodynamic modeling of a monoclonal antibody antagonist of glucagon receptor in male ob/ob mice.

Authors:  Yvonne Y Lau; Peiming Ma; Leonid Gibiansky; Renee Komorowski; Jin Wang; George Wang; Hai Yan; Murielle M Véniant; Tarundeep Kakkar
Journal:  AAPS J       Date:  2009-10-23       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.